icon- folder.gif   Conference Reports for NATAP  
 
  20th International AIDS Conference
July 20-25, 2014
Melbourne, Australia
 Back grey_arrow_rt.gif
 
 
 
HCV at IAC/2014-Melbourne
 
 
  Antifibrotic activity of dual CCR5/CCR2 antagonist cenicriviroc in a mouse model of renal fibrosis - (08/08/14)
 
The HCV Care "Cliff": High burden of HCV disease and poor access to HCV services among people who inject drugs in India - (08/06/14)
 
Body mass index (BMI) and change in levels of immune activation post- ART initiation in diverse low- and middle-income settings - (08/05/14)
 
Does the Addition of HCV Testing to a Rapid HIV Testing Program Impact HIV Test Acceptance? A Randomized Controlled Trial - (08/04/14)
 
Lack of Clinically Relevant Drug Interactions Between Elvitegravir plus Ritonavir Boosted-Atazanavir and Telaprevir (07/30/14)
 
TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 (07/21/14)
 
Abbvie 3D Regimen in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine (07/21/14)
 
All-Oral Therapy with Sofosbuvir Plus Ribavirin for the Treatment of HCV Genotype 1, 2,3 and 4 Infection in Patients Coinfected with HIV (PHOTON-2) (07/21/14)
 
High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2 - (07/21/14)
 
SAPPHIRE-II Subgroup Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-experienced Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)
 
SAPPHIRE-I Subpopulation Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-naïve Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)
 
Low Frequency of Anemia in Phase 3 Trials of ABT-450/r/ABT-267 and ABT-333 With Ribavirin in Treatment-naïve (SAPPHIRE-I) and Treatment-experienced (SAPPHIRE-II) Patients - (07/25/14)
 
Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (07/25/14)
 
High Response Rates With Triple-DAA Regimen (TURQUOISE-1) in People With HCV and HIV: Abbvie 3D - ABT-450/ritonavir, ombitasvir, and dasabuvir, with ribavirin - written by Mark Mascolini - (07/21/14)
 
SVR12 Rate 97% With 3 DAAs (Abbvie 3D) Plus Ribavirin in People on Opioid Replacement - (07/21/14)
 
Liver Markers Worse in Youth With Than Without HIV and Climb Over Time - Written by Mark Mascolini (07/21/14)
 
FIB-4 Predicts Major Liver Complications and Death in HCV+ People Starting ART - (07/21/14)